Pharvaris cash reaches €318 million in Q2

• Pharvaris reported second-quarter 2026 results with €318 million in cash and cash equivalents and continued development of deucrictibant.
• The company recorded a Q2 loss of €47.8 million, including €35.0 million in research and development expenses.
• Pharvaris expects CHAPTER-3 Phase 3 topline data for deucrictibant XR in hereditary angioedema in Q3 2026.

Pharvaris (NASDAQ:PHVS) reported second-quarter 2026 results with cash and cash equivalents of €318 million as of June 30, 2026, while advancing clinical programs for its oral bradykinin B2 receptor antagonist deucrictibant.

The company’s cash position increased from €292 million at year-end 2025 following a $132.3 million underwritten share offering, while Q2 2026 loss reached €47.8 million.

Pharvaris reported research and development expenses of €35 million and general and administrative expenses of €15.8 million during the quarter as it advanced clinical and regulatory activities.

The company expects topline data from CHAPTER-3, a Phase 3 prophylaxis trial of deucrictibant XR in hereditary angioedema, in the third quarter of 2026, while enrollment continues in CHAPTER-4 and the AAE-C1INH Phase 3 CREAATE study.

The FDA is also reviewing the deucrictibant immediate-release NDA, with a PDUFA action date of April 23, 2027, while the European Medicines Agency has validated the marketing authorization application.

Pharvaris also opened a U.S. expanded access program for deucrictibant IR and appointed Peng Lu as President to coordinate research, development and commercial functions.